Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex

Rob J.L. Willems*Comments to Author , Janetta Top*, Marga van Santen†, D. Ashley Robinson‡, Teresa M. Coque§, Fernando Baquero§, Hajo Grundmann†, and Marc J.M. Bonten*
Author affiliations: *University Medical Center Utrecht, Utrecht, the Netherlands; †National Institute for Public Health and the Environment, Bilthoven, the Netherlands,; ‡New York Medical College, Valhalla, New York, USA; §Hospital Ramon y Cajal, Madrid, Spain

Main Article

Figure 1

Clustering of 175 sequence types representing 411 isolates with eBURST (25). This algorithm identifies the founder of a complex or genogroup of related sequence types (ST) and subsequent patterns of evolutionary descent. The primary founder, indicated in blue, of a complex is defined as the ST with the largest number of single locus variants (SLVs). Larger complexes may contain secondary founders of additional lineages that have a number of SLVs of their own. These secondary founders are indicat

Figure 1. . Clustering of 175 sequence types representing 411 isolates with eBURST (25). This algorithm identifies the founder of a complex or genogroup of related sequence types (ST) and subsequent patterns of evolutionary descent. The primary founder, indicated in blue, of a complex is defined as the ST with the largest number of single locus variants (SLVs). Larger complexes may contain secondary founders of additional lineages that have a number of SLVs of their own. These secondary founders are indicated in yellow. Numbers correspond to ST numbers. The area of each circle corresponds to the number of isolates of the ST. All complexes (major and minor) are shown. In addition, 57 STs did not group into any of the complexes and were considered singletons (STs 13, 15, 30, 31, 36, 37, 38, 39, 42, 51, 52, 58, 59, 62, 65, 67, 68, 70, 72, 73, 74, 83, 84, 86, 89, 95, 96, 98, 99, 100, 102, 105, 107, 108, 110, 112, 114, 116, 118, 126, 129, 131, 142, 144, 145, 152, 153, 155, 162, 163, 164, 167, 168, 169, 170, 171, 172). The "epidemic" genetic complex-17 derived from secondary founder ST-17 is indicated. A measurement of statistical confidence in each of the assigned primary founders is made by a bootstrap resampling procedure (25).The predicted primary founders of the complexes 22, 94, 1, and 69 have a bootstrap value of 73%, 84%, 85%, and 59%, respectively.

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external